For every $28,000 the federal government spends on care for Alzheimer’s disease patients, it only spends $100 on Alzheimer’s disease research.
Modern drug efficacy trials are unnecessarily small, expensive, slow, and unrepresentative of true effectiveness in real-world patients.
Subjects in FDA Trials Are Not Representative of the Actual People Receiving Treatment External validity is the extent to which the results can be generalized to a population of interest. The population of interest is usually defined as the people the intervention is intended to help. Phase III clinical trials are designed to exclude a […]
Between 1990 and 2010, the incidence of celiac disease quadrupled in the United Kingdom.